ZA201607980B - Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms - Google Patents

Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms

Info

Publication number
ZA201607980B
ZA201607980B ZA2016/07980A ZA201607980A ZA201607980B ZA 201607980 B ZA201607980 B ZA 201607980B ZA 2016/07980 A ZA2016/07980 A ZA 2016/07980A ZA 201607980 A ZA201607980 A ZA 201607980A ZA 201607980 B ZA201607980 B ZA 201607980B
Authority
ZA
South Africa
Prior art keywords
myeloproliferative
treatment
telomerase inhibitors
neoplasms
disorders
Prior art date
Application number
ZA2016/07980A
Inventor
Monic J Stuart
Stephen Kelsey
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp filed Critical Geron Corp
Publication of ZA201607980B publication Critical patent/ZA201607980B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2016/07980A 2012-12-07 2016-11-17 Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms ZA201607980B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261734941P 2012-12-07 2012-12-07

Publications (1)

Publication Number Publication Date
ZA201607980B true ZA201607980B (en) 2022-04-28

Family

ID=50881627

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2016/07980A ZA201607980B (en) 2012-12-07 2016-11-17 Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms

Country Status (2)

Country Link
US (4) US9375485B2 (en)
ZA (1) ZA201607980B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9375485B2 (en) * 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
HUE042792T2 (en) * 2013-11-06 2019-07-29 Mayo Found Medical Education & Res Methods and materials for treating hematological malignancies
JOP20200257A1 (en) 2014-05-01 2017-06-16 Geron Corp Oligonucleotide Compositions and Methods of Making the Same
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
TW201919705A (en) * 2017-07-28 2019-06-01 美商健生生物科技公司 Methods of treating myelodysplastic syndrome
AU2019389005B2 (en) * 2018-11-29 2024-06-20 Geron Corporation Methods of treating myelodysplastic syndrome
EP3917397A4 (en) * 2019-01-28 2022-10-26 Board of Regents, The University of Texas System Metal chelator combination therapy for the treatment of cancer
MX2023000760A (en) * 2020-07-17 2023-02-13 Geron Corp Subcutaneous telomerase inhibitor compositions and methods for using same.
US20240108734A1 (en) * 2021-01-22 2024-04-04 The Regents Of The University Of California Methods for treating and ameliorating cancer

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5523389A (en) 1992-09-29 1996-06-04 Isis Pharmaceuticals, Inc. Inhibitors of human immunodeficiency virus
US7067497B2 (en) 1992-09-29 2006-06-27 Isis Pharmaceuticals, Inc. Modulation of telomere length by oligonucleotides having a G-core sequence
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5840490A (en) 1995-06-07 1998-11-24 Mcmaster University Telomerase activity associated with hematological and colorectal malignancies
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
KR100858465B1 (en) 1999-09-10 2008-09-16 제론 코포레이션 Oligonucleotide n3'?p5' thiophosphoramidates: their synthesis and use
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
CA2440322C (en) 2001-03-23 2014-09-09 Geron Corporation Oligonucleotide conjugates
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
DK3342425T3 (en) 2003-09-09 2020-03-16 Geron Corp MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION
US20050282893A1 (en) 2004-01-30 2005-12-22 Au Jessie L Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
SI1778711T1 (en) 2004-07-02 2017-11-30 Geron Corporation Synthesis of protected 3'-amino nucleoside monomers
FR2877013A1 (en) 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris INDENTIFICATION OF A JAK2 MUTATION INVOLVED IN THE VAQUEZ POLYGLOBULIA
US20060166221A1 (en) 2005-01-21 2006-07-27 Bahou Wadie F Methods of diagnosing essential thrombocythemia
WO2006113426A2 (en) 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of telomerase and tubulin activities
EP1876893B1 (en) 2005-04-15 2012-04-11 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
US20070224598A1 (en) 2006-03-15 2007-09-27 The Methodist Hospital Research Institute System and method for detection of mutations in JAK2 polynucleotides
US8153604B2 (en) 2006-04-24 2012-04-10 Geron Corporation CNS-tumor treatment method and composition
PL2101789T3 (en) 2006-10-30 2015-05-29 Geron Corp Combined telomerase inhibitor and gemcitabine for the treatment of cancer
US8785409B2 (en) * 2007-01-30 2014-07-22 Geron Corporation Compounds having anti-adhesive effects on cancer cells
ES2407957T3 (en) 2007-03-09 2013-06-17 Geron Corporation Treatment of carcinomas with a combination of inhibitors of the EGF pathway and telomerase
US8367078B2 (en) * 2007-06-06 2013-02-05 University Of Florida Research Foundation, Inc. Kinase inhibitor compounds
WO2010006291A1 (en) * 2008-07-10 2010-01-14 Nodality, Inc. Methods for diagnosis, prognosis and treatment
EP3719139B1 (en) 2008-10-17 2022-11-30 Geron Corporation Method for identification of sensitivity of a patient to telomerase inhibition therapy
WO2011098901A1 (en) 2010-02-12 2011-08-18 Ipsogen Asxl1 as a new diagnostic marker of myeloid neoplasms
MX361772B (en) 2011-10-19 2018-12-17 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (btk).
BR112015012507B1 (en) 2012-11-30 2023-03-07 Geron Corporation IN VITRO METHOD OF SELECTION OF AN INDIVIDUAL DIAGNOSED OR SUSPECTED OF HAVING CANCER
US9200327B2 (en) 2012-11-30 2015-12-01 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
US9375485B2 (en) * 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
HUE042792T2 (en) 2013-11-06 2019-07-29 Mayo Found Medical Education & Res Methods and materials for treating hematological malignancies

Also Published As

Publication number Publication date
US20170051287A1 (en) 2017-02-23
US20140163090A1 (en) 2014-06-12
US20200102564A1 (en) 2020-04-02
US9375485B2 (en) 2016-06-28
US20230183704A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
IL283943B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders
ZA202108991B (en) Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
ZA201607980B (en) Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
IL239355A0 (en) Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
ZA201408055B (en) Compositions and methods for the treatment of local pain
IL235127A (en) Hpn-100 for use in the treatment of nitrogen retention disorders
EP2825173A4 (en) Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies
EP2681209A4 (en) Compounds and methods for the treatment of pain and other disorders